5-(furan-3'-yl)-1,3,4-oxadiazole-2(3H)-thione | 101767-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(furan-3'-yl)-1,3,4-oxadiazole-2(3H)-thione
• 英文别名: 5-furan-3-yl-[1,3,4]oxadiazole-2-thiol；2-(furan-3-yl)-5-mercapto-1,3,4-oxadiazole；2-(3-furyl)-5-mercapto-1,3,4-oxadiazole；5-(furan-3-yl)-3H-1,3,4-oxadiazole-2-thione
• CAS: 101767-43-5
• 化学式: C₆H₄N₂O₂S
• 分子量: 168.176
• InChiKey: SEKFTJNJFFRRJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二甲氨基氯乙烷盐酸 、 5-(furan-3'-yl)-1,3,4-oxadiazole-2(3H)-thione 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 0.33h， 生成 2-<5'-(furan-3''-yl)-1',3',4'-oxadiazol-2'-ylthio>-N,N-dimethylethylamine
  参考文献：
  名称：

  Unfused Heterobicycles as Amplifiers of Phleomycin. VII> Some Bithiazoles; Thienyl-, Furanyl- and Thiazolyl-thiadiazoles and Related Oxadiazoles

  摘要：

  介绍了几种未融合杂环的合成方法，包括 4,5′- 和 2,4′- 双噻唑、5-(噻唑-4′和 5′-基)-1,3,4-噻二唑、5-(噻吩-2′-基)-、5-(呋喃-2′和 3′-基)-、噻二唑和相关的噁二唑，所有侧链都含有二烷基胺末端基团。报告了这些化合物作为博来霉素-G 放大剂的活性。

  DOI：

  10.1071/ch9851257
• 作为产物：
  描述：

  potassium 2-(furan-3-carbonyl)hydrazine-1-carbodithioate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.5h， 以81%的产率得到5-(furan-3'-yl)-1,3,4-oxadiazole-2(3H)-thione
  参考文献：
  名称：

  Unfused Heterobicycles as Amplifiers of Phleomycin. VII> Some Bithiazoles; Thienyl-, Furanyl- and Thiazolyl-thiadiazoles and Related Oxadiazoles

  摘要：

  介绍了几种未融合杂环的合成方法，包括 4,5′- 和 2,4′- 双噻唑、5-(噻唑-4′和 5′-基)-1,3,4-噻二唑、5-(噻吩-2′-基)-、5-(呋喃-2′和 3′-基)-、噻二唑和相关的噁二唑，所有侧链都含有二烷基胺末端基团。报告了这些化合物作为博来霉素-G 放大剂的活性。

  DOI：

  10.1071/ch9851257

文献信息

• [EN] NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] NOUVEAUX N-OXYDES DE DÉRIVÉS DE FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE ET LEUR UTILISATION MÉDICALE
  申请人：NEUROSEARCH AS

  公开号：WO2010086280A1

  公开（公告）日：2010-08-05

  This invention relates to novel N-oxides of certain furanyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及某些呋喃基-噁唑啉基-双氮杂双环庚烷衍生物的新型N-氧化物及其在制备药物组合物中的应用。该发明的化合物被发现是尼古丁乙酰胆碱受体的胆碱能配体，同时也是单胺受体和转运体的调节剂。由于它们的药理特性，该发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩有关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状等疾病或障碍具有用处。
• NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE
  申请人：Peters Dan

  公开号：US20110319397A1

  公开（公告）日：2011-12-29

  This invention relates to novel N-oxides of certain furanyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及某些呋喃基-噁唑基-哌嗪环壬烷衍生物的新型N-氧化物及其在制药组合物制备中的应用。本发明的化合物被发现是尼古丁乙酰胆碱受体的胆碱能配体和单胺类受体和转运体的调节剂，由于它们的药理特性，本发明的化合物可能对与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或障碍，与平滑肌收缩相关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，炎症、疼痛和化学物质滥用终止引起的戒断症状等多种疾病或障碍具有治疗作用。
• Bromide‐Catalyzed Electrochemical C <i>sp</i> ³ −H Oxidation of Acetonitrile: Stereoselective Synthesis of Heteroaryl Vinyl Sulfides
  作者：Jin‐Lin Wan、Jing‐Mei Huang

  DOI：10.1002/adsc.202200247

  日期：2022.8.2

  An electrochemical oxidative C−H/S−H cross-coupling reaction between acetonitrile and heteroaryl thiols has been developed. Me4NBr is employed as a redox catalyst to oxidize both the Csp3−H of acetonitrile and S−H of heteroaryl thiols. Heteroaryl vinyl sulfides were afforded under metal-free and oxidant-free reaction conditions in good yields and stereoselectivities with excellent functional group

  已经开发了乙腈和杂芳基硫醇之间的电化学氧化 C-H/S-H 交叉偶联反应。Me 4 NBr 用作氧化还原催化剂以氧化乙腈的 C sp 3 -H 和杂芳基硫醇的 S-H。在无金属和无氧化剂的反应条件下，杂芳基乙烯基硫化物具有良好的收率和立体选择性，具有优异的官能团耐受性。电化学方法的合成适用性因其易于扩展而进一步突出。
• US4278793A
  申请人：——

  公开号：US4278793A

  公开（公告）日：1981-07-14
• US4758556A
  申请人：——

  公开号：US4758556A

  公开（公告）日：1988-07-19